$CNTX
Context Therapeutics Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Context Therapeutics Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is CNTX down today? It is at $0.160 (-5.10%), and our scanner flagged it 30 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CNTX spikes, and full due diligence on CNTX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $CNTX 30 times in the last 30 days. Create a free account to track $CNTX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
The market is closed. Here is how CNTX traded in the last session, Friday (last price and move above). Our scanner fired 3 unusual-volume and momentum alerts on CNTX on Friday, peaking at 58.9x its normal volume.
Likely catalystContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline ProgressReported As of October 30, 2026, 27 patients with ovarian (n=20), testicular (n=4) and endometrial (n=3) cancer had received CTIM-76 in dose escalation cohorts, either QW at 22.5 to 560 µg (n=21) or Q3W at 280 µg (n=6).Reported As of October 30, 2026, median PFS was 5.6 months (95% CI: 1.2–7.4 months) among efficacy-evaluable PROC patients treated QW at biologically active doses.Reported Tumor reduction was observed across metastatic sites, including regression of 7 liver lesions in 4 patients (median −58%; range −16% to −100%)., from the latest SEC filing. Read it →Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Lehr Martin A. Officer | Bought (open market) | +100K 0.1% of company | added 12% | 920K | $70K at $0.700 | Jun 9, 25 |
Minai-Azary Jennifer Lynn Officer | Bought (open market) | +40K 0.04% of company | added 100% | 80K | $26K at $0.640 | Jun 6, 25 |
Levit Alex C. Officer | Bought (open market) | +20K 0.02% of company | added 100% | 29K | $12K at $0.580 | Jun 6, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.


The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
The market is closed. Here is how CNTX traded in the last session, Friday (last price and move above). Our scanner fired 3 unusual-volume and momentum alerts on CNTX on Friday, peaking at 58.9x its normal volume.
CNTX last traded at $0.160, down 5.10% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The CNTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CNTX 30 times in the last 30 days.
CNTX (Context Therapeutics Inc. Common Stock) trades on XNAS, with a market cap of about $15M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CNTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$CNTX discussion
Sign in to ask a question or join the discussion.